Patents Issued in December 14, 2021
-
Patent number: 11197872Abstract: The present disclosure relates to compounds and methods of eradicating cancer stem cells by combining inhibitors of oxidative metabolism and glycolytic metabolism. Also described are compounds and methods of identifying a combination of inhibitors of oxidative metabolism and glycolytic metabolism to treat cancer stem cells.Type: GrantFiled: April 20, 2018Date of Patent: December 14, 2021Assignee: LUNELLA BIOTECH, INC.Inventors: Michael P. Lisanti, Federica Sotgia
-
Patent number: 11197873Abstract: The present invention provides pharmaceutical compounds for the treatment of high-grade superficial bladder cancer in patent in need thereof. Further described are compositions of azolium salts for use in such treatment.Type: GrantFiled: June 3, 2020Date of Patent: December 14, 2021Assignees: The University of Akron, The Institute for Cancer ResearchInventors: Wiley Jay Youngs, Philip H. Abbosh, Michael Lee Stromyer, Marie Renee Southerland, Uttam Satyal, David Joseph Weader
-
Patent number: 11197874Abstract: A method of preventing contact allergies includes using at least one amphoteric chelating agent which includes a complex based on aluminium and on ethylenediaminetetraacetic acid or the trisodium salt thereof, having the general formula [Al(Y)Bn]c?Dc with B being OH?, BO2? or H+, Y being a tetracarboxylate which can be protonated four times to form ethylenediaminetetraacetic acid, n being an integer equal to 0, 1, 2 or 3, D being a counterion, preferably Na+, c being an integer equal to 0, 1, 2 or 3 and c? being a relative number having the same absolute value as c. A device, a part of which includes the amphoteric chelating agent, is also described.Type: GrantFiled: July 17, 2013Date of Patent: December 14, 2021Assignee: PREVOR INTERNATIONALInventors: Joel Blomet, Laurence Mathieu, Marie-Claude Meyer
-
Patent number: 11197875Abstract: Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.Type: GrantFiled: February 9, 2018Date of Patent: December 14, 2021Assignee: ABBOTT LABORATORIESInventors: Rachael Buck, Geralyn O. Duska-McEwen, Joseph P. Schaller
-
Patent number: 11197876Abstract: The invention provides compositions and methods for treating asthma in a subject in need thereof comprising administering chemically synthesized secoisolaricirecinol diglucoside (SDG), and in particular, a racemic mixture of the SDG (LGM2605), stereoisomers thereof, metabolites thereof, and analogs thereof. Also provided are methods for treating or preventing ozone-induced damage in a subject in need thereof.Type: GrantFiled: October 5, 2018Date of Patent: December 14, 2021Assignees: THE TRUSIEES OF THE UNIVERSITY OF PENNSYLVANIA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Melpo Christofidou-Solomidou, Angela Haczku
-
Patent number: 11197877Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, E-selectin antagonists are described and pharmaceutical compositions comprising at least one of the same.Type: GrantFiled: March 12, 2018Date of Patent: December 14, 2021Assignee: GLYCOMIMETICS. INC.Inventors: John L Magnani, John M Peterson, Arun K Sarkar, Yusuf U Vohra, Myung-Gi Baek
-
Patent number: 11197878Abstract: The present specification relates to an anti-inflammatory composition including a novel quercetin-based compound isolated from a post-fermented tea, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, and may be widely used in various areas related to anti-inflammation.Type: GrantFiled: June 11, 2018Date of Patent: December 14, 2021Assignee: AMOREPACIFIC CORPORATIONInventors: Yong-Deog Hong, Jeong-Kee Kim
-
Patent number: 11197879Abstract: This invention relates to a flavonoid composition that includes eriocitrin. The flavonoid may be included in a complex with other bioflavonoids. The composition may also include neoeriocitrin. This invention also relates to methods of using the composition, including for reducing IL-6 or MCP-1 treating inflammation, and treating symptoms of metabolic syndrome.Type: GrantFiled: February 6, 2020Date of Patent: December 14, 2021Assignees: INGREDIENTS BY NATURE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTUREInventors: Robert M. Brewster, John A. Manthey
-
Patent number: 11197880Abstract: Provided herein is a composition comprising eriocitrin, and uses thereof for managing pre-diabetes and diabetes. The composition may be useful for increasing GLP-1 levels.Type: GrantFiled: March 27, 2020Date of Patent: December 14, 2021Assignee: INGREDIENTS BY NATURE, LLCInventors: Robert M. Brewster, Thais Cesar, Carolina Barbosa Ribeiro
-
Patent number: 11197881Abstract: A reactivation composition for activating or re-activating expression of a silenced X chromosome gene in a cell includes a non-cytotoxic histone deacetylase (HDAC) inhibitor. The reactivation composition includes the non-cytotoxic HDAC inhibitor and may further include a DNA methylation inhibitor. A method of activating or re-activating expression of a silenced X chromosome gene in a cell includes administering a reactivation composition including a non-cytotoxic HDAC inhibitor. The method of activating or re-activating expression of a silenced X chromosome gene may further includes administering a reactivation composition that includes a non-cytotoxic HDAC inhibitor and an inhibitor of DNA methylation.Type: GrantFiled: October 27, 2017Date of Patent: December 14, 2021Assignee: California Institute of TechnologyInventors: Mitchell Guttman, Chun-Kan Chen
-
Patent number: 11197882Abstract: This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections, such as Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infection with the disclosed compounds.Type: GrantFiled: December 7, 2018Date of Patent: December 14, 2021Assignee: Emory UniversityInventors: George R. Painter, Gregory R. Bluemling, Michael G. Natchus, David Guthrie
-
Patent number: 11197883Abstract: Disclosed herein are UBAP2L targeting agents and use of such agents for the treatment of a neurodegenerative disorder. Further disclosed herein are methods of monitoring the progression of a neurodegenerative disorder and methods of determining the efficacy of a neurodegenerative disorder therapy.Type: GrantFiled: June 4, 2019Date of Patent: December 14, 2021Assignee: The Regents of the University of CaliforniaInventors: Eugene Yeo, Sebastian Markmiller, En-Ching Luo
-
Patent number: 11197884Abstract: Provided herein are methods, compounds, and compositions for modulating expression of at least one member of the Notch signaling pathway in a cell or individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a respiratory disorder associated with excessive mucus production in an individual.Type: GrantFiled: August 17, 2018Date of Patent: December 14, 2021Assignee: Ionis Pharmaceuticals, Inc.Inventor: Tamar R. Grossman
-
Patent number: 11197885Abstract: Described herein are materials and methods useful for the treatment of neurodegenerative disorders and bone disorders, as well as healing wounds, in a subject. Materials described herein include polysaccharide digestive products resulting from the enzymatic hydrolysis of low acyl gellan gum. Also described herein are pharmaceutical compositions comprising one or more of such materials, and methods for their preparation and use.Type: GrantFiled: March 2, 2017Date of Patent: December 14, 2021Assignee: The University of ToledoInventors: Joshua J. Park, Dong-Shik Kim
-
Patent number: 11197886Abstract: The present invention discloses pharmaceutical compositions comprising ester derivatives of hyaluronic acid for use as a topical treatment in disorders of the vaginal mucosa characterised by loss of elasticity and hydration, such as vaginal dryness and/or atrophic vaginitis; said compositions can also be used successfully to lubricate the genital mucosa.Type: GrantFiled: October 4, 2019Date of Patent: December 14, 2021Assignee: FIDIA FARMACEUTICI S.p.A.Inventors: Laura Pilotto, Giovanni Gennari, Anna Maria Zanellato
-
Patent number: 11197887Abstract: Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.Type: GrantFiled: August 16, 2019Date of Patent: December 14, 2021Assignee: TRICIDA, INC.Inventors: Gerrit Klaerner, Eric F. Connor, Randi K. Gbur, Matthew J. Kade, Paul H. Kierstead, Jerry M. Buysse, Michael J. Cope, Kalpesh N. Biyani, Son H. Nguyen, Scott M. Tabakman
-
Patent number: 11197888Abstract: The conjugation of luteinizing hormone-releasing hormone (LHRH) with activated cisplatin using a malonate linker gives rise to a new Platinum-LHRH conjugate that effectively targets tumor cells that express the LHRH receptor. The Pt-LHRH conjugate may be used in a method for killing or inhibiting the growth of a tumor cell, especially in late state, highly invasive and aggressive stage IV tumors and in reoccurring tumors.Type: GrantFiled: October 12, 2018Date of Patent: December 14, 2021Assignee: Eastern Kentucky UniversityInventors: Margaret Ndinguri, Lindsay Calderon
-
Patent number: 11197889Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.Type: GrantFiled: November 6, 2017Date of Patent: December 14, 2021Assignees: ABT Holding Company, Oregon Health & Science UniversityInventors: Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
-
Patent number: 11197890Abstract: The current invention is related to the prevention and treatment of diseases including cancer, autoimmune disease, and infectious disease using CXC chemokines and the receptors to which they agonize. It has been found that certain chemokines, including CXCL4, CXCL9, CXCL10, and CXCL12 have various effects on toll-like receptors in various cell types and these can be utilized for disease treatment and prevention.Type: GrantFiled: December 12, 2017Date of Patent: December 14, 2021Assignee: New York Society for the Relief of the Ruptured and Crippled, maintaining the Hospital for Special SurgeryInventor: Franck Barrat
-
Patent number: 11197891Abstract: Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway and cells, such as immune cells, prepared in vitro with the compounds. The compounds and cells can be used to treat a number of conditions, including infectious diseases, hyperproliferative disorders, inborn errors of metabolism, chronic immunometabolic diseases, autoimmune diseases, organ transplant rejection, inflammatory disorders, and chronic pain, among others.Type: GrantFiled: November 16, 2018Date of Patent: December 14, 2021Assignee: LANDOS BIOPHARMA, INC.Inventors: Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
-
Patent number: 11197892Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: April 13, 2021Date of Patent: December 14, 2021Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Heiko Schuster, Franziska Hoffgaard, Jens Fritsche, Oliver Schoor, Toni Weinschenk, Daniel Johannes Kowalewski, Chih-Chiang Tsou
-
Patent number: 11197893Abstract: A pure platelet-rich plasma (P-PRP) composition as an alternative to conventional antibiotic treatment of subclinical mastitis caused by Gram-positive bacteria in bovine including five live platelets and leukocytes, an anticoagulant, and an activating substance.Type: GrantFiled: November 8, 2016Date of Patent: December 14, 2021Assignee: Universidad de CaldasInventors: Alejandro Ceballos, Jorge U. Carmona
-
Patent number: 11197894Abstract: Compositions that include extracts from sources of immune modulators that include nanofraction immune modulator molecules (i.e., molecules having molecular weights of about 3,000 Da and less) are disclosed. These compositions may also include other immune modulators, such as transfer factor. Administration of compositions with extracts that include nanofraction immune modulator molecules modulates the cell-mediated immunity (e.g., down-regulates undesired T cell activity) of a subject to which such compositions are administered. When administered with transfer factor, the combination of nanofraction immune modulator molecules and transfer factor down-regulates undesired T cell activity while increasing, or up-regulating, T cell activity against pathogens and other undesirable entities, such as cancer cells and other aberrant or mutated cells. Assays and assay techniques for evaluating the immune modulation capabilities of various substances are also disclosed.Type: GrantFiled: November 11, 2019Date of Patent: December 14, 2021Assignee: 4Life Patents, LLCInventors: David A. Lisonbee, Calvin W. McCausland, Richard H. Bennett, Brent M. Vaughan, Shane M. Lefler
-
Patent number: 11197895Abstract: Biologically low invasive vessels are filled with biological factors that have the activity of mobilizing specific functional cells in the body. The vessels are indwelled in the body. After specific functional cells are mobilized into the vessels, the vessels are removed from the body to collect functional cell populations mobilized to the vessels. Alternatively, the cells are directly collected from the vessels indwelled in the body.Type: GrantFiled: August 11, 2017Date of Patent: December 14, 2021Assignees: STEMRIM INC., OSAKA UNIVERSITYInventors: Katsuto Tamai, Takehiko Yamazaki, Takenao Chino, Yasufumi Kaneda
-
Patent number: 11197896Abstract: The present technology relates generally to formulations comprising egg white protein, methods of manufacturing egg protein formulations and uses for egg protein formulations. In particular, several embodiments are directed to egg protein formulations for oral administration in immunotherapy of subjects affected by egg allergies.Type: GrantFiled: August 25, 2015Date of Patent: December 14, 2021Assignee: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.Inventor: Howard V. Raff
-
Patent number: 11197897Abstract: The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistant Enterococci infection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria Clostridium scindens and/or the bacteria Blautia producta contribute substantially to resistance against vancomycin-resistant Enterococci infection or colonization. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids in the case of Clostridium scindens.Type: GrantFiled: May 8, 2020Date of Patent: December 14, 2021Assignee: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: Eric Pamer, Peter McKenney, Silvia Caballero
-
Patent number: 11197898Abstract: The present invention discloses a novel fructophilic lactic acid producing bacteria Bacillus coagulans strain FF-7 (MTCC 25235) and the process of isolation and characterization of the bacteria. The invention also discloses the biological applications/therapeutic use of fructophilic lactic acid producing bacteria in increased utilization of fructose from food stuff and in the managing disorders related to high fructose intake.Type: GrantFiled: May 13, 2019Date of Patent: December 14, 2021Assignee: Sami Labs LimitedInventors: Muhammed Majeed, Kalyanam Nagabhushanam, Furqan Ali, Sivakumar Arumugam, Shaheen Majeed, Kirankumar Beede
-
Patent number: 11197899Abstract: The present invention relates to a composition comprising as antifungal active agent at least 2·1010 CFU of lactobacilli and a sulfur-containing compound for use as a first-line treatment for candidiasis and for recurrent candidiasis.Type: GrantFiled: March 1, 2017Date of Patent: December 14, 2021Assignee: NEXBIOME THERAPEUTICSInventor: Adrien Nivoliez
-
Patent number: 11197900Abstract: A food composition is disclosed which comprises the acid-resistant bacterial strain Lactobacillus acetotolerans LE36. The L. acetotolerans LE36 strain has anti-inflammatory properties. The food composition can be further provided as a pharmaceutical composition.Type: GrantFiled: May 3, 2019Date of Patent: December 14, 2021Assignee: TAIWAN ENZYME VILLAGE CO. LTD.Inventors: Chia-Li Wei, Yu-Ting Wang, Tsung-Yi Li, Ya-Chen Huang, Po-Jen Cheng
-
Patent number: 11197901Abstract: The present invention provides an active substance of Lactic Acid Bacteria, a composition comprising thereof and its use for promoting longevity, especially for increasing Cisd2 gene expression, reducing mitochondrial damage and delaying aging conditions such as nerve degeneration and sarcopenia.Type: GrantFiled: August 15, 2019Date of Patent: December 14, 2021Assignee: GRAPE KING BIO LTD.Inventors: Chin-Chu Chen, Yen-Lien Chen, Shin-Wei Lin, Yen-Po Chen, Ci-Sian Wang, Yu-Hsin Hou, Yang-Tzu Shih, Ching-Wen Lin, Ya-Jyun Chen, Jia-Lin Jiang
-
Patent number: 11197902Abstract: Methods for treatment and compositions are provided for increasing the health of humans, livestock, and companion animals. More particularly, dietary supplements (also referred to as PPA (prebiotic, probiotic, antibodies) compositions) for treating humans, livestock, and companion animals, and methods for making and using them for treatment of various conditions are disclosed.Type: GrantFiled: June 23, 2017Date of Patent: December 14, 2021Assignee: IG Biosciences CorporationInventors: Valentino Grant, Dayna J. Campbell, George D. Ranglin
-
Patent number: 11197903Abstract: The present invention relates to a composition containing a bean extract extracted by low-concentration, low-grade alcohol or fractions thereof. The composition exhibits excellent effects in improving blood circulation, improving obesity, and preventing diabetes, hyperlipidemia and the like, and exhibits the effects of alleviating or treating the symptoms of diabetes, hyperlipidemia, and the like. The present invention also relates to a method for improving blood circulation and vascular health.Type: GrantFiled: February 4, 2019Date of Patent: December 14, 2021Assignee: AMOREPACIFIC CORPORATIONInventors: Hyun Jung Shin, Jin Kwan Kim, Chae Wook Kim, Kyung Mi Joo, Yeon Su Jeong, Kyung Min Lim, Dae-Bang Seo, Yung Hyup Joo, Sang Jun Lee, Young-Ho Park
-
Patent number: 11197904Abstract: The present invention relates to the area of pharmaceutical compositions. More particularly, the present invention relates to a series of pharmaceutical compositions (PTM) containing phyto-polyphenols (P), clinical drugs with selective targets (T) and a metal ions (M) and the methods thereof for use in prevention and therapy of infectious diseases, neurodegenerative diseases, dementia, diabetes, obesity, metabolic syndromes, osteoporosis, cancers and/or chronic pain.Type: GrantFiled: January 20, 2019Date of Patent: December 14, 2021Assignees: Chung Shan Medical UniversityInventor: Shoei-Yn Lin-Shiau
-
Patent number: 11197905Abstract: A composition includes a target pharmaceutical or biological agent, a solution containing the target pharmaceutical or biological agent, and substrate that is soluble in the solution. The substrate is capable of being solidified via a solidification process and the solidification process causes the substrate to become physically or chemically cross-linked, vitrified, or crystallized. As a result of the solidification process, particles are formed. The target pharmaceutical or biological agent within the solution retains proper conformation to ultimately produce a desired effect.Type: GrantFiled: July 24, 2019Date of Patent: December 14, 2021Assignee: TissueGen, Inc.Inventors: Jennifer Seifert, Paul R. Sood, Brent B. Crow, Kevin D. Nelson, Nickolas B. Griffin, Alpeshkumar P. Patel, Paul A. Hubbard
-
Patent number: 11197906Abstract: The present disclosure relates to, among other things, compositions and methods for treating an inflammatory condition including, but not limited to, ocular inflammation, dry eye disease, and ocular neuropathic pain. One aspect of the present disclosure relates to a composition comprising (a) chemerin or a fragment or analog thereof and (b) a lipid entity linked to the chemerin or fragment or analog thereof.Type: GrantFiled: January 23, 2017Date of Patent: December 14, 2021Assignees: On Target Therapeutics LLC, Trustees of Tufts College, Tufts Medical CenterInventors: Charles Cohen, Krishna Kumar, Alan S. Kopin, Benjamin N. Harwood, Venkata S. Raman, Pedram Hamrah
-
Patent number: 11197907Abstract: Cultures of Delftia bacteria are disclosed. Antimicrobial agents derived therefrom are also disclosed.Type: GrantFiled: March 28, 2018Date of Patent: December 14, 2021Assignees: Ministry of Health, State of Israel, Sami Shamoon College of Engineeing (R.A), Tel HaShomer Medical Research Infrastructure and Services Ltd.Inventors: Israel Nissan, Noa Lea Tejman-Yarden, Chaim Rubinovitz, Yakov Davidov, Galia Rahav, Ari Robinson, Yoram Shotland
-
Patent number: 11197908Abstract: Disclosed herein are peptoids and methods for attenuating inflammatory responses, and more particularly RAGE-associated inflammatory responses.Type: GrantFiled: July 17, 2019Date of Patent: December 14, 2021Assignees: The Board of Trustees of the University of Arkansas, University of South CarolinaInventors: Shannon Servoss, Melissa Moss, Lauren Wolf
-
Patent number: 11197909Abstract: The disclosure features non-irritating pharmaceutical compositions containing CD101 in pharmaceutical acceptable salt (e.g., CD101 acetate) or neutral form. The pharmaceutical compositions can be intravenously administered to a subject to treat fungal infections (e.g., candidiasis) in the subject.Type: GrantFiled: July 11, 2018Date of Patent: December 14, 2021Assignee: Cidara Therapeutics, Inc.Inventors: Kenneth Bartizal, Paul Daruwala, David Hughes, Martin Patrick Hughes, Navdeep B. Malkar, Balasingam Radhakrishnan, Anuradha Vaidya
-
Patent number: 11197910Abstract: The present invention relates to the use of phosphotidylserine or pathogenic sugar targeted therapeutics for the management and treatment of microbial infections, including Zika, Dengue, West Nile, Ebola, H1N1, enteroviruses, Leishmaniasis, Malaria and Coronaviruses SARS-COV.Type: GrantFiled: August 19, 2020Date of Patent: December 14, 2021Assignee: VITRUVIAE LLCInventors: Mahiuddin Ahmed, Sonia Sequeira
-
Patent number: 11197911Abstract: The present invention provides for a novel peptide inhibitor and method for treating neurological disorders related to a hexanucleotide (GGGGCC) repeat expansion in the non-coding region of the C9ORF72 gene. Also disclosed are related compositions and kits for therapeutic use in the treatment of the pertinent diseases.Type: GrantFiled: November 2, 2017Date of Patent: December 14, 2021Assignee: The Chinese University of Hong KongInventors: Ho Yin Edwin Chan, Jacky Chi-Ki Ngo, Qian Zhang
-
Patent number: 11197912Abstract: Compositions for and methods of preventing, reversing or treating viral infection-induced organ failure provided. The compositions are also suitable for treating and/or preventing COVID-19 and influenza. The compositions and methods employ MG53, which can be in the form of recombinant human MG53. The MG53 may also be administered as a composition that expresses and releases MG53 after in vivo administration of said composition to a subject.Type: GrantFiled: February 25, 2021Date of Patent: December 14, 2021Assignee: OHIO STATE INNOVATION FOUNDATIONInventors: Jianjie Ma, Jacob S. Yount, Matthew A. Sermersheim, Adam D. Kenney, Xinyu Zhou, Bryan A. Whitson, Nahush A. Mokadam, Tao Tan, Chuanxi Cai
-
Patent number: 11197913Abstract: A method of treating an IL-12/23-related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4 weeks, after 16 weeks and after 28 weeks, and increasing the dosing interval after 28 weeks to an increased interval, e.g., every 16, 20 or 24 weeks.Type: GrantFiled: August 14, 2020Date of Patent: December 14, 2021Assignee: JANSSEN BIOTECH, INC.Inventors: Marc Chevrier, Kamyar Farahi, Newman Yeilding
-
Patent number: 11197914Abstract: The invention relates to uses of polypeptide compounds having dual target agonist effect on glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). Characterized by high enzymolysis stability, high biological activity and no adverse reaction, the polypeptide compounds are capable of reducing abnormal increase of triglycerides and total cholesterol in blood induced by diabetes mellitus and high fat diet, reducing liver enzyme level, reducing liver injury and fibrosis stage, and preventing or treating non-alcoholic fatty liver diseases (NAFLDs), hyperlipemia and arteriosclerosis.Type: GrantFiled: May 11, 2016Date of Patent: December 14, 2021Inventors: Xianxing Jiang, Rui Wang
-
Patent number: 11197915Abstract: CTP-modified human growth hormone polypeptides and pharmaceutical formulations and pharmaceutical compositions comprising the same and methods of producing, and using the same are disclosed.Type: GrantFiled: July 1, 2016Date of Patent: December 14, 2021Assignee: OPKO BIOLOGICS LTD.Inventors: Fuad Fares, Udi Eyal Fima
-
Patent number: 11197916Abstract: Long-term stable pharmaceutical formulations of lyophilized recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations are described.Type: GrantFiled: January 25, 2019Date of Patent: December 14, 2021Assignee: Takeda Pharmaceutical Company LimitedInventors: Kurt Schnecker, Eva Haidweger, Peter Turecek
-
Patent number: 11197917Abstract: Formulations having a protein component, in which the protein contains one or more digestion-aiding proteins, and/or one or more immunoprotective proteins. The formulations may also contain a fat component, a carbohydrate component, and vitamins and minerals. These formulations can be used to provide nutritional support to a subject, either as dietary supplements or as a primary source of nutrition, such as for an infant formula.Type: GrantFiled: December 1, 2017Date of Patent: December 14, 2021Assignee: ByHeart, Inc.Inventors: Ron Belldegrun, Mia Funt
-
Patent number: 11197918Abstract: The present invention relates to a pharmaceutical composition for preventing or treating neovascular disease, including a collagen and a 34-mer pigment epithelium derived factor (PEDF) peptide as an active ingredient, more specifically, the combined administration of the collagen type I and the 34-mer pigment epithelium derived factor peptide increases the short antiangiogenic activity cycle of the PEDF and extends the dosage range of the PEDF to solve the discomfort and the side effects accordingly due to the conventional frequent injections and thus it can be applied as a therapeutic agent for various neovascular diseases.Type: GrantFiled: June 8, 2018Date of Patent: December 14, 2021Assignee: NexThera Co., Ltd.Inventors: Sea Gwang Park, Kug Hwan Roh, Hyun Woong Kim, Sung Jae Park
-
Patent number: 11197919Abstract: Chimeric transmembrane immunoreceptors (CAR) which include an extracellular domain targeted to HER2, a transmembrane region, a costimulatory domain and an intracellular signaling domain are described.Type: GrantFiled: November 4, 2016Date of Patent: December 14, 2021Assignee: City of HopeInventors: Saul J. Priceman, Stephen J. Forman, Christine E. Brown
-
Patent number: 11197920Abstract: The present invention relates to particles, particularly virus-like particles (VLPs), comprising fusion polypeptides comprising selected repeat units derived from the repeating regions of Type I and Type II circumsporozoite proteins (CSP) of Plasmodium vivax (Pv), together with an amino acid sequence derived from the C-terminal PvCSP sequence. In some embodiments, the fusion polypeptide additionally comprises an amino acid sequence derived from the N-terminal PvCSP sequence and/or a surface antigen polypeptide derived from Hepatitis B virus (HBV-S). The invention also relates to nucleotide sequences coding for such fusion polypeptides, vectors and plasmids comprising such nucleotide sequences, and host cells comprising such vectors and plasmids. The invention additionally relates to compositions, particularly vaccine compositions, comprising the fusion polypeptides or VLPs for use as vaccines for the prevention of malaria.Type: GrantFiled: May 18, 2017Date of Patent: December 14, 2021Assignee: Oxford University Innovation LimitedInventor: Arturo Reyes-Sandoval
-
Patent number: 11197921Abstract: The present invention provides methods for making polysaccharide-protein conjugates in which polysaccharides, typically from bacteria, are conjugated to a carrier protein by reductive amination under conditions which improve conjugation reaction consistency, increase consumption of protein during conjugation reaction, generate conjugates of higher molecular weight, and/or reduce the levels of free cyanide in the conjugate reaction product. The polysaccharide-protein conjugates obtained using these methods are useful for inclusion in multivalent vaccines.Type: GrantFiled: January 30, 2018Date of Patent: December 14, 2021Assignee: Merck Sharp & Dohme Corp.Inventors: Jitin Bajaj, Michael Albert Winters, Emily Wen, Jian He